Literature DB >> 32468677

Retrospectively assessed subjective effects of initial opioid use differ between opioid misusers with opioid use disorder (OUD) and those who never progressed to OUD: Data from a pilot and a replication sample.

Arpana Agrawal1, Paul W Jeffries1, A Benjamin Srivastava2, Vivia V McCutcheon1, Michael T Lynskey3, Andrew C Heath1, Elliot C Nelson1.   

Abstract

Attempts to identify opioid users with increased risk of escalating to opioid use disorder (OUD) have had limited success. Retrospectively assessed subjective effects of initial opioid misuse were compared in a pilot sample of opioid misusers (nonmedical use ≤60 times lifetime) who had never met criteria for OUD (N = 14) and heroin-addicted individuals in treatment for OUD (N = 15). Relative to opioid misusers without a lifetime OUD diagnosis, individuals with OUD reported greater euphoria and other positive emotions, activation, pruritus, and internalizing symptoms. Consistent with these findings, proxy Addiction Research Center Inventory (ARCI) Amphetamine Group, and Morphine Benzedrine Group scale mean item scores were significantly higher in those with OUD. Replication was attempted in opioid misusers with (N = 25) and without OUD (N = 25) who were assessed as part of an ongoing genetic study. We observed similar significant between-group differences in individual subjective effect items and ARCI scale mean item scores in the replication sample. We, thus confirm findings from prior reports that retrospectively assessed subjective responses to initial opioid exposure differ significantly between opioid users who do, and do not, progress to OUD. Our report extends these findings in comparisons limited to opioid misusers. Additional research will be necessary to examine prospectively whether the assessment of subjective effects after initial use has predictive utility in the identification of individuals more likely to progress to OUD.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  initial opioid use; opioid misusers; opioid use disorder; subjective effects

Mesh:

Substances:

Year:  2020        PMID: 32468677      PMCID: PMC8142810          DOI: 10.1002/jnr.24643

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  29 in total

1.  Drug Overdose Deaths in the United States, 1999-2017.

Authors:  Holly Hedegaard; Arialdi M Miniño; Margaret Warner
Journal:  NCHS Data Brief       Date:  2018-11

2.  Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids.

Authors:  Xian-Yu Liu; Zhong-Chun Liu; Yan-Gang Sun; Michael Ross; Seungil Kim; Feng-Fang Tsai; Qi-Fang Li; Joseph Jeffry; Ji-Young Kim; Horace H Loh; Zhou-Feng Chen
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

Review 3.  The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction.

Authors:  Andrew Kolodny; David T Courtwright; Catherine S Hwang; Peter Kreiner; John L Eadie; Thomas W Clark; G Caleb Alexander
Journal:  Annu Rev Public Health       Date:  2015-01-12       Impact factor: 21.981

4.  Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans.

Authors:  L A Marsch; W K Bickel; G J Badger; J P Rathmell; M D Swedberg; B Jonzon; C Norsten-Höög
Journal:  J Pharmacol Exp Ther       Date:  2001-12       Impact factor: 4.030

5.  A validity study of the SSAGA--a comparison with the SCAN.

Authors:  M Hesselbrock; C Easton; K K Bucholz; M Schuckit; V Hesselbrock
Journal:  Addiction       Date:  1999-09       Impact factor: 6.526

6.  A comparison of morphine-induced locomotor activity and mesolimbic dopamine release in C57BL6, 129Sv and DBA2 mice.

Authors:  N P Murphy; H A Lam; N T Maidment
Journal:  J Neurochem       Date:  2001-11       Impact factor: 5.372

7.  Gender differences in risk factors for aberrant prescription opioid use.

Authors:  Robert N Jamison; Stephen F Butler; Simon H Budman; Robert R Edwards; Ajay D Wasan
Journal:  J Pain       Date:  2009-11-27       Impact factor: 5.820

8.  ANKK1, TTC12, and NCAM1 polymorphisms and heroin dependence: importance of considering drug exposure.

Authors:  Elliot C Nelson; Michael T Lynskey; Andrew C Heath; Naomi Wray; Arpana Agrawal; Fiona L Shand; Anjali K Henders; Leanne Wallace; Alexandre A Todorov; Andrew J Schrage; Nancy L Saccone; Pamela A F Madden; Louisa Degenhardt; Nicholas G Martin; Grant W Montgomery
Journal:  JAMA Psychiatry       Date:  2013-03       Impact factor: 21.596

9.  Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers.

Authors:  James P Zacny; Sandra Gutierrez
Journal:  Psychopharmacology (Berl)       Date:  2003-08-29       Impact factor: 4.530

10.  Evidence of CNIH3 involvement in opioid dependence.

Authors:  E C Nelson; A Agrawal; A C Heath; R Bogdan; R Sherva; B Zhang; R Al-Hasani; M R Bruchas; Y-L Chou; C H Demers; C E Carey; E D Conley; A K Fakira; L A Farrer; A Goate; S Gordon; A K Henders; V Hesselbrock; M Kapoor; M T Lynskey; P A F Madden; J A Moron; J P Rice; N L Saccone; S G Schwab; F L Shand; A A Todorov; L Wallace; T Wang; N R Wray; X Zhou; L Degenhardt; N G Martin; A R Hariri; H R Kranzler; J Gelernter; L J Bierut; D J Clark; G W Montgomery
Journal:  Mol Psychiatry       Date:  2015-08-04       Impact factor: 15.992

View more
  2 in total

1.  Can initial experiences with drugs predict future drug abuse risks?

Authors:  Neil B Varshneya; Kelly E Dunn; Caitlyn J Grubb; Sandra I Okobi; Andrew S Huhn; Cecilia L Bergeria
Journal:  Exp Clin Psychopharmacol       Date:  2022-03-10       Impact factor: 3.492

Review 2.  Dopamine Supersensitivity: A Novel Hypothesis of Opioid-Induced Neurobiological Mechanisms Underlying Opioid-Stimulant Co-use and Opioid Relapse.

Authors:  Justin C Strickland; Cassandra D Gipson; Kelly E Dunn
Journal:  Front Psychiatry       Date:  2022-04-15       Impact factor: 5.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.